
Opinion|Videos|August 7, 2024
Cosmic-313 and Alternate Lines of Therapy for Poor Risk Metastatic RCC
Oncology specialists analyze the COSMIC-313 trial results and explore alternative treatment strategies for patients with poor-risk metastatic renal cell carcinoma.
Episodes in this series





































